Abstract
Therapeutic efficacy of a synthetic somatostatin analogue for the treatment of carcinoid tumors is still controversial. In vivo studies performed in our laboratory showed that a somatostatin analogue, SMS 201-995, significantly inhibited growth of human pancreatic carcinoid (BON) tumors xenotransplanted into athymic nude mice. In the present study, however, SMS 201-995 did not inhibit in vitro growth of BON cells, but rather SMS 201-995 stimulated growth in a dose-dependent fashion. The growth-stimulatory effect was likely mediated through the reduction of cyclic AMP production. Unsuccessful treatment of certain types of carcinoid tumor with SMS 201-995 may be partly due to the direct growth-stimulatory effect of SMS 201-995 on carcinoid cells.
Original language | English |
---|---|
Pages (from-to) | 577-581 |
Number of pages | 5 |
Journal | Biochemical and Biophysical Research Communications |
Volume | 185 |
Issue number | 2 |
DOIs | |
State | Published - Jun 15 1992 |
Bibliographical note
Funding Information:This work was supported by grants from the National Institutes of Health (NIH) (PO1 DK 35608, 5R37 DK15241), the American Cancer Society (PDT-220) and the John Sealy Endowment Fund. The authors would like to thank Jell Hsieh for her technical assistance and Sherry Carter for her assistance in the preparation of this manuscript.
ASJC Scopus subject areas
- Biophysics
- Biochemistry
- Molecular Biology
- Cell Biology